Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
Collin M. Blakely(City College of San Francisco), Trever G. Bivona(University of California, San Francisco), Aleah F. Caulin, Philip C. Mack(UC Davis Comprehensive Cancer Center), Richard B. Lanman(C.T. de Wit Graduate School for Production Ecology and Resource Conservation), Charles Swanton(The Francis Crick Institute), Gareth A. Wilson(The Francis Crick Institute), Petros Giannikopoulos(University of California, San Francisco), Hatim Husain(University of California, San Diego), Caroline E. McCoach(Memorial Sloan Kettering Cancer Center), Robert C. Doebele(Aurora University), Anibal R. Cordero, David R. Gandara(University of California, Davis), Thomas B.K. Watkins(The Francis Crick Institute), Victor Olivas(University of California, San Francisco), Kimberly C. Banks(Guardant (United States)), Matthew A. Gubens(University of California, San Francisco), Nicholas McGranahan(CRUK Lung Cancer Centre of Excellence), John St. John, Ashley Maynard(ETH Zurich), Beatrice Gini(Ludwig Cancer Research), Jacob J. Chabon(Foresight Science & Technology (United States)), Nicolai J. Birkbak(Brigham and Women's Hospital), Jonathan W. Riess(University of California Davis Medical Center), Wei Wu(Children's Hospital of Zhejiang University), Victoria Wang(IIT@Harvard), Maximilian Diehn(Stanford University), Andrew D. Simmons(Clovis Oncology (United States)), Julia Rotow(University of California, San Francisco)
Cited by 590
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k